Where is Buprenorphine Dispensed to Treat Opioid Use Disorders? the Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties

Milbank Quarterly

Volumn 93, Issue 3, 2015, Pages 561-583

  Stein, Bradley D ^a,b   Pacula, Rosalie Liccardo ^a   Gordon, Adam J ^b,c   Burns, Rachel M ^a   Leslie, Douglas L ^d   Sorbero, Mark J ^a   Bauhoff, Sebastian ^a   Mandell, Todd W ^e   Dick, Andrew W ^a  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e Community Substance Abuse Centers ^*  (United States)

Author keywords

buprenorphine; health policy; opioid related disorders; substance abuse treatment

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANTAGONIST;

CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; HEALTH CARE FACILITY; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; MEDICOLEGAL ASPECT; METHADONE TREATMENT; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; URBAN RURAL DIFFERENCE; DRUG DEPENDENCE TREATMENT; HEALTH CARE DELIVERY; HEALTH SERVICE; LEGISLATION AND JURISPRUDENCE; PHYSICIAN; POLICY; PRESCRIPTION; PRIVATE PRACTICE; RURAL HEALTH CARE; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

BUPRENORPHINE; DRUG PRESCRIPTIONS; HEALTH SERVICES ACCESSIBILITY; HUMANS; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; PHYSICIANS; PRIVATE PRACTICE; PUBLIC POLICY; RURAL HEALTH SERVICES; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; UNITED STATES; URBAN HEALTH SERVICES;

EID: 84941045961     PISSN: 0887378X     EISSN: 14680009     Source Type: Journal    
DOI: 10.1111/1468-0009.12137     Document Type: Review

References (68)

1. Office of Applied Studies SAMHSA. The DASIS report. The national survey of substance abuse treatment services (N-SSATS). 2012. http://www.oas.samhsa.gov/2k3/NSSATS/NSSATS.pdf. Accessed June 23, 2013.
2. Murphy S, Xu J, Kochanek K,. Deaths: final data for 2010. Natl Vital Stat Rep. 2013; 61 (4).
3. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL,. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011; 12 (4): 657-667.
4. Mattick RP, Kimber J, Breen C, Davoli M,. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008 (2).
5. National Institute on Drug Abuse. Principles of Effective Treatment for Criminal Justice Populations. Rockville, MD: National Institute on Drug Abuse; 2006.
6. National Institute on Drug Abuse National Quality Forum. Evidence-Based Treatment Practices for Substance Use Disorders: Workshop Proceedings. Washington, DC: National Institute on Drug Abuse; 2005.
7. Volkow ND,. NIDA at 30: committed to scientific solutions for drug addiction problems. NIDA Notes. 2004. http://www.drugabuse.gov/NIDA-notes/NNvol19N1/DirRep. Accessed January 15, 2007.
8. Fiellin DA, Pantalon MV, Chawarski MC, et al., Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006; 355 (4): 365-374.
9. Kakko J, Svanborg KD, Kreek MJ, Heilig M,. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003; 361 (9358): 662-668.
10. National Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA. 1998; 280 (22): 1936-1943.
11. Ball J, Ross A,. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome. New York, NY: Springer-Verlag; 1991.
12. Fiellin DA, O'Connor PG,. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002; 347 (11): 817-823.
13. Fudala PJ, Bridge TP, Herbert S, et al., Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349 (10): 949-958.
14. Sees KL, Delucchi KL, Masson C, et al., Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000; 283 (10): 1303-1310.
15. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE,. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000; 343 (18): 1290-1297.
16. Volkow ND, Frieden TR, Hyde PS, Cha SS,. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370 (22): 2063- 2066.
17. American Methadone Treatment Association. Methadone Maintenance Program and Patient Census in the US. New York, NY: American Methadone Treatment Association; 1998.
18. O'Brien CP., A 50-year-old woman addicted to heroin: review of treatment of heroin addiction. JAMA. 2008; 300 (3): 314-321.
19. Clark RE, Samnaliev M, Baxter JD, Leung GY,. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011; 30 (8): 1425-1433.
20. US Department of Health and Human Services, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. The determinations report: a report on the physician waiver program established by the Drug Addiction Treatment Act of 2000 ("DATA"). Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2006.
21. Ducharme L, Abraham A,. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treatment Prev Policy. 2008; 3 (1): 17-27.
22. Substance Abuse and Mental Health Services Administration, Department of Health and Human Services. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule. Federal Register. 2012; 77 (235): 72752-72761.
23. Oliva EM, Maisel NC, Gordon AJ, Harris AH,. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011; 13 (5): 374-381.
24. Kissin W, McLeod C, Sonnefeld J, Stanton A,. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006; 25 (4): 91.
25. Fiellin DA,. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007; 1 (2): 62-67.
26. Arfken CL, Johanson CE, di Menza S, Schuster CR,. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010; 39 (2): 96-104.
27. Stein BD, Gordon AJ, Dick AW, et al., Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treatment. 2015; 48 (1): 104-111.
28. Koch AL, Arfken CL, Schuster CR,. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Dependence. 2006; 83: 274-278.
29. Ling W, Jacobs P, Hillhouse M, et al., From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treatment. 2010; 38: S53-S60.
30. Knudsen HK, Abraham AJ, Johnson JA, Roman PM,. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treatment. 2009; 37 (3): 307-312.
31. Knudsen HK, Ducharme LJ, Roman PM,. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treatment. 2006; 30 (4): 363-373.
32. Ducharme LJ, Roman PM,. Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption. J Subst Abuse Treatment. 2009; 37 (1): 90-94.
33. Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C,. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Dependence. 2012; 123 (1-3): 72-78.
34. Gordon AJ, Trafton JA, Saxon AJ, et al., Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug Alcohol Dependence. 2007; 90 (2-3): 292-296.
35. Baxter JD, Clark RE, Samnaliev M, Leung GY, Hashemi L,. Factors associated with Medicaid patients' access to buprenorphine treatment. J Subst Abuse Treatment. Published online April 2, 2011; 41: 88-96.
36. Gordon AJ, Kavanagh G, Krumm M, et al., Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011; 25 (2): 215-224.
37. Oliva EM, Trafton JA, Harris AH, Gordon AJ,. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013; 39 (2): 103-107.
38. Oliva EM, Harris AH, Trafton JA, Gordon AJ,. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Drug Alcohol Dependence. 2012; 122 (3): 241-246.
39. Woody GE, Poole SA, Subramaniam G, et al., Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008; 300 (17): 2003-2011.
40. Dick AW, Pacula RL, Gordon AJ, et al., Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff (Millwood). 2015; 34 (6): 1028-1034.
41. US Department of Agriculture Economic Research Service. 2013 rural-urban continuum codes. http://www.ers.usda.gov/data-products/rural-urban- continuum-codes.aspx-.VAcgRcVdXOE. Accessed September 3, 2014.
42. National Institute on Drug Abuse. America's addiction to opioids: heroin and prescription drug abuse. http://www.drugabuse.gov/about-nida/legislative- activities/testimony-to-congress/2014/americas-addiction-to-opioids-heroin-prescription-drug-abuse. Accessed December 9, 2014.
43. Mattick RP, Breen C, Kimber J, Davoli M,. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009 (3): CD002209.
44. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C,. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003; 98 (4): 441-452.
45. Lovegrove MC, Mathew J, Hampp C, Governale L, Wysowski DK, Budnitz DS,. Emergency hospitalizations for unsupervised prescription medication ingestions by young children. Pediatrics. 2014; 134 (4): e1009-1016.
46. Kim HK, Smiddy M, Hoffman RS, Nelson LS,. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics. 2012; 130 (6): e1700-1703.
47. Martin TC, Rocque MA,. Accidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999-2009. Curr Drug Safety. 2011; 6 (1): 12-16.
48. Pedapati EV, Bateman ST,. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pediatr Crit Care Med. 2011; 12 (2): e102-107.
49. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP,. Factors contributing to the rise of buprenorphine misuse: 2008-2013. Drug Alcohol Dependence. 2014; 142: 98-104.
50. Johanson CE, Arfken CL, di Menza S, Schuster CR,. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Dependence. 2012; 120 (1-3): 190-195.
51. Daniulaityte R, Falck R, Carlson RG,. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Dependence. 2012; 122 (3): 201-207.
52. Lavonas EJ, Severtson SG, Martinez EM, et al., Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treatment. 2014; 47 (1): 27-34.
53. US Food and Drug Administration. NDA 22-410: SUBOXONE® (buprenorphine and naloxone) sublingual film CIII; buprenorphine (opioid partial agonist-antagonist); naloxone (opioid antagonist). Reference ID: 3496928. Silver Spring, MD; 2014.
54. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG,. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014; 174 (12): 1947-1954.
55. Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andrée T, McNicholas L,. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008; 17 (6): 459-462.
56. Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andrée T, McNicholas L,. Physician training is never a failure. Am J Addict. 2009; 18 (4): 337- 338.
57. Sigmon SC., The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry. 2015; 72 (4): 395.
58. Walley AY, Alperen JK, Cheng DM, et al., Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008; 23 (9): 1393-1398.
59. American Psychiatric Association. How to prepare for a visit from the Drug Enforcement Administration (DEA) regarding buprenorphine prescribing. Arlington, VA: American Psychiatric Association; 2011.
60. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine treatment of opioid addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
61. Olsen Y, Sharfstein JM,. Confronting the stigma of opioid use disorder-and its treatment. JAMA. 2014; 311 (14): 1393-1394.
62. American Society of Addiction Medicine. State Medicaid reports. http://www.asam.org/advocacy/aaam/state-medicaid-reports. Accessed January 22, 2015.
63. Burns RM, Pacula RL, Bauhoff S, et al., Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013. Subst Abus. In press.
64. Wisniewski AM, Dlugosz MR, Blondell RD,. Reimbursement and practice policies among providers of buprenorphine-naloxone treatment. Subst Abuse. 2013; 34 (2): 105-107.
65. Knudsen HK, Abraham AJ, Roman PM,. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011; 5 (1): 21-27.
66. Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH,. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014; 49 (6): 1964-1979.
67. Haddad MS, Zelenev A, Altice FL,. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Dependence. 2013; 131 (1-2): 127-135.
68. Stein BD, Dick AW, Sorbero M, et al., Patterns of buprenorphine use among Medicaid-enrolled individuals with opioid use disorders. Paper presented at: 2014 Addiction Health Services Research (AHSR) Conference; October 15, 2014; Boston, MA.